The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Genome-wide association study (GWAS) of the efficacy of capecitabine, oxaliplatin, and bevacizumab in metastatic colorectal cancer in the CAIRO2 trial of the Dutch Colorectal Cancer Group (DCCG).
H. Guchelaar
No relevant relationships to disclose
J. Pander
No relevant relationships to disclose
S. Bohringer
No relevant relationships to disclose
T. van der Straaten
No relevant relationships to disclose
Y. Ariyurek
No relevant relationships to disclose
J. Houwing-Duistermaat
No relevant relationships to disclose
H. Gelderblom
No relevant relationships to disclose
C. J. A. Punt
No relevant relationships to disclose